Proposed actions of GIP and GLP1 receptor agonist in human

Overview

GIP and GLP-1 RA's mechanism of action

This Class for

• Physician
• Resident / Fellow

What I will learn?

• Learn how GIP and GLP-1 RA's mechanism of action make it an innovative and novel treatment for obesity
  
  
  
  
  Disclaimer
  
  This content is approved by Eli Lilly and Company (“Lilly”). This content is intellectual property of Lilly and its reproduction needs Lilly's prior permission
  (This information/content is intended to Health Care Providers only)
  
  For adverse events and safety reporting: email: saudi_pharmacovigilance@lilly.com
  24 /7 mobile : +966 567 868 843 working hours: +966 11 461 7800 , Ext: 1
  For Lilly product information: email: SAUDI_MEDINFOQUERIES@lilly.com
  For further information, please contact:
  Eli Lilly and Company, Scientific Office P.O. Box 92120 Riyadh 11653, Kingdom of Saudi Arabia. Tel: +966 11 461 7800 Fax: +966 111 217 9900 email: Saudi_Pharmacovigilance@lilly.com
  
  
  PP-LD-SA-0457

Related Classes

• Post-GLP Podcast: needs of patients on GLP-1 RA with basal insulin
• Second generation basal insulin in advancing T2D therapy
• Soliqua and Unmet Needs Webinar Summary - William Polonsky and Kathrine
• Timely insulin initiation to limit disease progression
• SURMOUNT-5 Clinical Update–Now Published
• Bridging pathophysiology and epidemiology for better understanding of obesity
• Introducing Mounjaro: A Once-Weekly, First-in-Class GIP and GLP-1 Receptor Agonist
• Supporting Patients with Obesity Through Comprehensive Treatment